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The objectives of an anticoagulation clinic are to:
• Optimise control of a patient’s anticoagulation
•  Educate patients, because warfarin has a narrow therapeutic 
range.
Patients should be referred to an anticoagulation clinic 
only after being adequately anticoagulated. The referring 
doctor should perform any adjustments to the initial dosage 
of warfarin.  The general care of the patient remains the 
responsibility of the referring doctor. Any bleeding and 
thrombo-embolic events must be reported and managed by the 
referring doctor and/or referred to an appropriate specialist.
1. Contraindications to warfarin 
therapy 
Ensure there are no contraindications to warfarin therapy. 
The absolute contraindications to warfarin are:
• The presence of severe bleeding
• Non-compliance, and
•  The first trimester of pregnancy and from 34 - 36 weeks 
onwards. 
Warfarin is associated with a dose-dependent (>5 mg1) 
teratogenic effect between 6 and 12 weeks’gestation.2,3 In 
addition warfarin therapy is associated with an increased risk 
of miscarriage and prematurity, and of fetal bleeding (including 
intracranial haemorrhage resulting in brain damage) at any 
time during pregnancy but in particular at delivery.4 
Warfarin is therefore generally avoided during pregnancy, 
and patients are given a low-molecular-weight heparin 
(LMWH) that does not cross the placenta.5 A specialist with 
expertise in this field should monitor pregnant patients. 
Warfarin6 and heparins can safely be administered to nursing 
mothers.
In the absence of controlled trials, it is difficult to make 
reliable recommendations about optimal anticoagulant therapy 
in pregnant patients with mechanical prosthetic valves. The use 
of closely monitored twice-daily LMWH therapy throughout 
pregnancy (anti-Xa level 1 - 1.2 U/l) is favoured.7,8
Some relative contraindications include:
•  Uncontrolled hypertension (i.e. systolic blood pressure >180 
mmHg, diastolic >100 mmHg)
• Severe liver disease, and
• Recent surgery involving the nervous system, spine or eye.
2. Target INR and duration of therapy
The goal of anticoagulant therapy with warfarin is to 
administer the lowest effective dose to maintain the target 
international normalised ratio (INR).
•  The target INR is 2.5 (range 2.0 - 3.0) for most indications, 
including: 
• Deep-vein thrombosis treatment and prophylaxis
• Pulmonary embolism 
•  Cardiac conditions, including atrial fibrillation, left 
ventricular systolic dysfunction, the first 3 months 
following anterior myocardial infarction, mural thrombus.
•  The target INR is 3.0 (range 2.5 - 3.5) for the following 
indications: 
•  Most patients with mechanical prosthetic valves. However, 
a range of 2.0 - 3.0 is recommended for low-risk patients 
with bi-leaflet mechanical valves (such as the St Jude 
Medical device) in the aortic position.9          
• Patients with warfarin failure.
3. Monitoring the INR at initiation of 
therapy
At the initiation of therapy, the INR should be monitored 
initially after 2 - 3 days and then daily until a therapeutic 
range is achieved. 
Frequent adjustments of dosage are not recommended 
because changes in warfarin dosage may take several days to 
affect the INR. 
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4. Monitoring the INR once stable
Once stable, the INR should be monitored every 1 - 4 
weeks.10
•  Patients on a chronic, stable dose of warfarin should be 
tested every 4 weeks. 
•  Patients with an unstable dose response will require more 
frequent monitoring (every 1 - 2 weeks).
•  More frequent monitoring is indicated for patients with 
mechanical prosthetic valves in the first postoperative 
month. This is a period during which the patient is at high 
risk for thrombo-embolism, and the target INR should be 
maintained.2,11
•  More frequent monitoring is indicated when medications are 
changed, when there is intercurrent illness, and in the pre- 
and postoperative periods.
5. Fluctuations of the INR
Fluctuations of the INR outside the desired target range 
should be investigated. The following causes should be 
considered:
• Patient compliance and patient error
• Change in warfarin dosage
• Intercurrent illness
• Dietary interactions 
• Drug interactions  
• Liver and renal dysfunction 
•  Patients >60 years, who may require a lower warfarin dose 
as the clearance of warfarin decreases with age.10 In addition, 
elderly patients are more likely to have medical conditions 
or concurrent drug use that may influence the INR.12 These 
patients should be carefully monitored. 
• Laboratory error, viz.:
• Correct citrate concentration (3.2%)
• Adequate filling of tube 
•  The first draw specimen should not be used for 
anticoagulation studies 
• The sample must be processed within 4 hours of collection. 
The recommended dosage adjustments for patients with 
an INR target range of 2.0 - 3.0 are tabulated in Appendix 1. 
NB: These are general guidelines and management should be 
individualised according to the bleeding risk.
6.  The INR record card
Patients should be monitored with an INR record card.
7. Duration of anticoagulant therapy
The duration of anticoagulant therapy should be 
individualised according to the patient’s thrombotic risk.13 
The indications for a patient’s anticoagulant therapy should 
be reviewed 6-monthly by the referring doctor.
In general:
•  Patients with venous thrombo-embolism (VTE) with a 
reversible risk factor should be treated for at least 3 months.14 
A d-dimer level should be checked before stopping warfarin 
therapy. Prolonged warfarin therapy may be indicated for 
patients with persistently raised d-dimers.15,16
•  Patients with an idiopathic deep-vein thrombosis (DVT) and 
all patients with pulmonary emboli should be treated for at 
least 6 months.17 
•  Patients with recurrent DVTs or persistent risk factors may 
benefit from longer anticoagulation. However, anticoagulant 
treatment for >2 years has been shown to be associated with 
an increased risk of bleeding.14,18
8. Patient education (see Appendix 2)
•  Warfarin tablets are taken once a day (usually in the 
evening), preferably at the same time. Some patients, 
however, may find it more convenient to take their dose in 
the morning. INR tests should be performed in the morning. 
This is merely for the convenience of adjusting the dose 
within 12 hours of the test. 
•  Importance of therapy and the duration of required 
anticoagulation (as indicated by the treating/referring 
doctor).
• Compliance.
•  Bleeding and thrombotic complications; and when to come to 
hospital.
• The importance of INR monitoring.
• Consistent vitamin K content of the diet.
• Review of current medications.
• Drug and illness interactions.
9. Dental procedures
•  In most cases, no change in the intensity of anticoagulation is 
needed. There are a number of documented cases of embolic 
events in patients whose warfarin therapy was discontinued 
for dental treatment.2 The INR can be lowered to a target of 
2.0.19,20
• Low risk of bleeding – continue warfarin.
•  High risk of bleeding – refer to the referring doctor to 
consider discontinuation of warfarin. If necessary discuss 
with the cardiologist whether it is safe to discontinue.
•  Cyclokapron tablets 1 g crushed and dissolved in half a glass 
of water used as a mouthwash 2 hours preoperatively then 
3 times a day postoperatively, will assist in controlling local 
bleeding, without the need to interrupt warfarin.21
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10. Surgical procedures
•  Assess the patient’s risk for venous thrombo-embolism in 
relation to the underlying condition for which warfarin 
therapy is required and the risk of bleeding associated with 
the surgical procedure. 
•  After warfarin therapy is stopped, it takes about 4 days for 
the INR to reach 1.5. Once the INR reaches 1.5, surgery can 
safely be performed. 
•  After warfarin therapy is restarted, it takes about 3 days for 
the INR to reach 2.0.22 
•  If warfarin is withheld for 4 days before surgery and 
treatment is restarted as soon as possible after surgery, 
patients can be expected to have a sub-therapeutic INR 
for approximately 4 days. The risk of thrombo-embolism 
associated with a few days of peri-operative sub-therapeutic 
anticoagulation is generally very low. However, the risk of 
bleeding associated with postoperative intravenous heparin 
therapy is often relatively high.
Low risk9 – patients with conditions such as atrial fibrillation 
(without stroke) and venous thrombo-embolism for >3 
months:  
•  If a patient’s INR is between 2.0 and 3.0, 4 scheduled doses of 
warfarin should be withheld to allow the INR to fall to 1.5 or 
less before surgery. Warfarin should be withheld for a longer 
period if the INR is normally maintained above 3.0 or if it is 
necessary to achieve a lower level depending on the type of 
surgery.23
•  The INR should be measured a day before surgery. 
•  Patients on warfarin for more than 3 months do not need pre-
operative heparin, unless surgical prophylaxis is indicated. 
If surgical prophylaxis is required, start LMWH (e.g. 
enoxaparin 40 mg subcutaneously daily) or unfractionated 
heparin (5 000 U subcutaneously daily) until 12 - 24 hours 
before the procedure.
•  Postoperative prophylaxis (e.g. enoxaparin 40 mg 
subcutaneously daily) is recommended until warfarin 
therapy is re-established and the INR is above 2.0. The 
original dose of warfarin can be started 8 - 12 hours 
postoperatively. 
High-risk patients23-25 with conditions such as mechanical 
valve replacements and venous thrombo-embolism for <3 
months:
• Interruption of anticoagulant therapy should be avoided.26
•  Elective surgery should be avoided in the first month after an 
acute episode of venous or arterial thrombo-embolism. 
•  Pre- and postoperative prophylaxis is indicated while the 
INR is below 2.0.
•  If the patient is on anticoagulant therapy for a venous 
thrombo-embolism for more than 1 month but less than 3 
months, pre-operative prophylaxis is not indicated unless 
additional risk factors for recurrent venous thrombo-
embolism are present. 
•  For patients with a low risk of bleeding, warfarin therapy 
can be continued at a lower dose. This can be achieved by 
halving the warfarin dose 7 days pre-operatively.27
•  The INR should be measured a day before surgery. Aim for a 
range of 1.5 - 2.0.2 The desirable INR will depend on the type 
of surgery.
•  If the INR is <1.5 prior to surgery, start unfractionated 
heparin (5 000 - 10 000 U as an intravenous infusion in 200 
ml normal saline at 33 ml/h). LMWH (enoxaparin 1 mg/kg 
subcutaneously twice a day) can also be used.8,28 LMWHs 
should be administered with caution in patients with renal 
failure, and anti-Xa monitoring is mandatory.
•  Partial thromboplastin time (PTT) monitoring is indicated 12-
hourly to monitor unfractionated heparin. Aim to achieve a 
PTT of 1.5 - 2 times the normal PTT. 
•  Continuous intravenous heparin therapy should be 
discontinued at least 6 hours before surgery. This should 
be individualised and determined by the risk of bleeding 
associated with the surgical procedure.  
•  Heparin therapy should not be restarted until 12 hours 
after major surgery and should be delayed even longer if 
there is any evidence of bleeding from the surgical site. 
Unfractionated heparin should be restarted without a bolus, 
at no more than the expected maintenance infusion rate.29 
The PTT should be checked 12 hours after restarting therapy 
to allow time for a stable anticoagulant response.
The committee wishes to thank Dr Elise Schapkaitz for researching, 
referencing and collating the guidelines and Hilda Jacobson for 
editing the manuscript.
Appendix 1: Dosage adjustments for 
patients on maintenance warfarin 
therapy9 (target INR 2.0 - 3.0)
INR Dosage adjustment
<1.5 Increase weekly dose by ~20%
1.5 - 1.9 Increase weekly dose by ~10%
2.0 - 3.0 No change
3.1 - 3.9 No change. Recheck weekly
If persists decrease weekly dose by   
~10 - 20%
4.0 - 5.0 Omit one dose
Decrease weekly dose by ~10 - 20% and 
recheck in 5 - 7 days 
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Important considerations:
•  All patients with an INR >10.0 and/or significant bleeding 
must be referred to the referring doctor.
•  The target INR in patients with mechanical valve 
replacements is 2.5 - 3.5. 
•  Avoid the use of IV vitamin K in patients with mechanical 
valve replacements because of the risk of valve thrombosis.2 
Oral vitamin K 1 - 2 mg (0.1 - 0.2 ml Konakion) can be 
administered to such patients with an INR >10.0 or at high 
risk of bleeding.33,34 Alternatively, these patients should be 
admitted to hospital for monitoring while the INR falls 
spontaneously.
•  All patients with mechanical valve replacements and 
complications should be referred to the referring cardiologist.
Appendix 2: Information for patients 
on warfarin therapy
What is warfarin?
Warfarin is an oral anticoagulant, which prolongs the time 
taken for blood to clot. This reduces the possibility of clot 
formation. 
It is prescribed for conditions such as an irregular heart 
rhythm, artificial heart valves, clotting in veins, or stroke. 
Too much warfarin may lead to serious bleeding, and too 
little will not prevent clotting. Warfarin must be taken exactly 
as prescribed and must be monitored with regular lab tests.
Before you start warfarin treatment:
•  Tell your health care professional about all other illnesses you 
have and all the medicines, including over-the-counter drugs 
and special diets you are on. 
•  Many medications such as aspirin,35,36 ibuprofen (e.g. Brufen 
and Myprodol) and herbal medicines, such as gingko, 
increase the effect of warfarin. 
• Some sedatives decrease the effect of warfarin. 
•  For women: tell your health care professional if you are, or 
are planning to become pregnant. Warfarin can harm the 
developing fetus.
• If you are breastfeeding, you may safely take warfarin. 
During your warfarin treatment:
•  Keep a written record of your target range, INR results and 
dosage. This can help you and your health care professional 
manage your warfarin therapy.
•  Proper use. Warfarin should be taken once a day, preferably 
at the same time at night. Store the medication in a cool dry 
place, away from the reach of children.
•  Regular blood tests are important. A blood test called an 
‘INR’ is required to determine how much warfarin you need. 
Because many factors can influence how your body responds 
to warfarin, you will need to have regular blood tests. Your 
health care professional will determine the range of INR 
that is right for you and decide how frequently it should be 
checked. Normally, the INR is checked at least once a month, 
but more frequent testing may be appropriate in some 
situations. Try to have your test performed in the morning so 
your dose can be adjusted if indicated. 
•  Keep the vitamin K content of your diet consistent. 
Changes in the amount of vitamin K in your diet can affect 
the warfarin level. Avoid changes to your normal eating 
patterns. Continue to eat a balanced diet containing a variety 
of foods. Limit yourself to a small portion of one of the 
following vitamin K-rich foods per day: cauliflower, cabbage, 
broccoli, spinach, Brussels sprouts, avocado pear, liver and 
marog. One orange or half a glass of orange juice or half a 
grapefruit may be taken per day.
•  Notify your health care professional of any new 
medications taken. 
•  Avoid heavy or binge alcohol consumption. Moderate, 
consistent alcohol intake does not affect warfarin therapy.
•  Other precautions. Avoid any activity or sport that may 
result in a serious fall or other injury. Use a soft toothbrush, 
and brush and floss gently to prevent bleeding from the 
gums. 
5.0 - 9.0 
without 
significant 
bleeding
Stop warfarin therapy
Consider oral low-dose vitamin K         
1 - 2.5 mg po ( 0.1 - 0.25 ml Konakion) 
and monitor daily30,31
Vitamin K may need to be repeated
Monitor INR every 2 - 3 days until in 
the therapeutic range 
Once INR in target range restart 
warfarin
Decrease weekly dose by ~10 - 20% and 
recheck in 5 - 7 days
>9.0 without 
significant 
bleeding
Stop warfarin therapy
Give oral vitamin K 5 mg po              
(0.5 ml  Konakion)31,32 
Vitamin K may need to be repeated
Monitor INR daily until therapeutic
Once INR in target range restart 
warfarin
Decrease weekly dose by ~20% and 
recheck in 3 - 5 days 
Monitor frequently until stable
Prolonged INR 
and significant 
bleeding
Stop warfarin therapy 
Call doctor
Give prothrombin complex concentrates 
(50 U/kg) or fresh-frozen plasma         
(15 - 20 ml/kg) or Bioplasma FDP 
Give vitamin K 1 - 2 mg IVI slowly
Monitor INR daily
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• Inform your health care professional if you: 
• Develop side-effects (see below) 
• Miss a dose 
• Change your diet or medications 
• Become ill 
• Have a surgical or dental procedure planned
• Plan to travel. 
•  If you become pregnant, contact your health care 
professional immediately.
•  Side-effects. Bleeding is the most serious potential side-
effect of warfarin. If you experience any of the following 
symptoms, call your health care professional:
• Red or dark brown urine 
• Red or black stool
• Severe headache or dizzy spells
• Unusual weakness
• Excessive menstrual bleeding
• Prolonged bleeding from gums or nose
• Unusual pain, swelling or bruising
• Dark, purplish or mottled fingers or toes
• Vomiting or coughing up blood.
•  If you plan to travel: Carry identification explaining the 
reason you are taking warfarin (including the target INR, and 
current dosage). Carry a copy of your warfarin record sheet. 
Make sure you have enough warfarin tablets. Carry your 
medications with you at all times. Try to maintain your usual 
diet.
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